We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Controlling lymph node micrometastases by neoadjuvant chemotherapy affects the prognosis in advanced esophageal squamous cell carcinoma.
- Authors
Hiraki, Yoko; Kimura, Yutaka; Imano, Motohiro; Kato, Hiroaki; Iwama, Mitsuru; Shiraishi, Osamu; Yasuda, Atsushi; Shinkai, Masayuki; Makino, Tomoki; Motoori, Masaaki; Yamasaki, Makoto; Miyata, Hiroshi; Satou, Takao; Satoh, Taroh; Furukawa, Hiroshi; Yano, Masahiko; Doki, Yuichiro; Yasuda, Takushi
- Abstract
Purpose: The purpose of this study is to determine the clinical significance of micrometastases after neoadjuvant chemotherapy (NAC) and the difference in controlling micrometastases using different NAC regimens in resectable advanced esophageal squamous cell carcinoma (ESCC). Methods: We analyzed patients with ESCC who underwent esophagectomy with lymph node dissection after NAC with Adriamycin + cisplatin + 5-fluorouracil (ACF) or docetaxel + cisplatin + 5-fluorouracil (DCF). Micrometastasis was defined as a single isolated cancer cell or cluster of cancer cells on the cervical, recurrent nerve, or abdominal LNs as shown by immunohistochemical staining with anti-cytokeratin antibody (AE1/AE3). The associations between micrometastases, recurrence, prognosis, and regimen differences were investigated. Results: One hundred and one cases (ACF group: 51 cases; DCF group: 50 cases) were analyzed. Micrometastases occurred in 24 patients (23.8%): 17/51 (33.3%) in the ACF group and 7/50 (13.5%) in the DCF group (p = 0.0403). The 5-year recurrence-free survival (RFS) rates for patients without (n = 77) and with (n = 24) micrometastases were 62 and 32%, respectively, (hazard ratio, 2.158; 95% confidence interval, 1.170–3.980; stratified log-rank test, p = 0.0115). A multivariate analysis showed that stage pN1 or higher and micrometastases were significant risk factors affecting RFS. Conclusion: In resectable advanced ESCC, controlling micrometastases in the LNs after NAC varied by regimen and may be associated with preventing ESCC recurrence.
- Subjects
MICROMETASTASIS; SQUAMOUS cell carcinoma; NEOADJUVANT chemotherapy; LYMPH nodes; LYMPHADENECTOMY; PROGNOSIS
- Publication
Surgery Today, 2021, Vol 51, Issue 1, p118
- ISSN
0941-1291
- Publication type
Article
- DOI
10.1007/s00595-020-02059-7